[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","commit":"28a6975696","date":"2026-09-10","author":"Jude Gomila","message":"Tone pass: solution and mechanism first; frightening figures behind a click","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"burden","before":"\"~85% of lung cancer; lung cancer kills ~1.8 million people a year, more than any other cancer.\"","after":"\"~85% of lung cancer. Low-dose CT screening catches cancers in people at high risk while they are still curable (NLST, NELSON), and a dozen targetable drivers each have a matched drug. Lung cancer still accounts for a..."},{"field":"tldr","before":"\"Non-small-cell lung cancer is the biggest cancer killer, and the proving ground for precision medicine: a dozen targetable mutations, immunotherapy for the rest, and ADCs and bispecifics arriving now.\"","after":"\"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases ar..."},{"field":"stateOfArt","before":"[\"5-year PFS 60% with lorlatinib in ALK+ disease.\", \"Adjuvant osimertinib halves death risk.\", \"First regimen to beat osimertinib (MARIPOSA) and first to beat pembrolizumab (ivonescimab, China).\"]","after":"[\"5-year PFS 60% with lorlatinib in ALK+ disease.\", \"Adjuvant osimertinib after surgery for EGFR-mutant disease roughly halves the risk of the cancer returning or of dying from it (ADAURA).\", \"First regimen to beat os..."}]},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"tldr","before":"\"The biggest cancer killer, and the proving ground for precision medicine: a dozen targetable mutations, immunotherapy for the rest, and ADCs and bispecifics arriving now.\"","after":"\"Non-small-cell lung cancer is the biggest cancer killer, and the proving ground for precision medicine: a dozen targetable mutations, immunotherapy for the rest, and ADCs and bispecifics arriving now.\""}]},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Screening\", approach: \"Annual low-dose CT for high-risk smokers (NLST, NELSON); AI nodule scoring emerging.\", refs: [\"ct\", \"radiology-ai-screening\"] },\n      { setting: \"Early stage\", approach: \"Su...","after":"[\n      { setting: \"Screening\", approach: \"Annual low-dose CT for high-risk smokers (NLST, NELSON); AI nodule scoring emerging.\", refs: [\"ct\", \"radiology-ai-screening\"], guideline: { version: \"NCCN Guidelines: Non-Sma..."}]}]